Parkinson's disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis.

The current study presents preliminary data regarding the development and validation of a rating system designed to classify PD patients into clinical subgroups. Using portions of the Unified Parkinson's Disease Rating Scale, a ratio value was derived, yielding three patient subtypes: a tremor-dominant group (T), an akinetic-rigid group (AR), and a mixed group (MX). Validation of the schema was conducted by grouping PD surgical candidates into specific disease subtypes and evaluating differences in neurotransmitter profiles among disease subtypes and non-PD neurological controls. High pressure liquid chromatography analysis of ventricular cerebrospinal fluid indicated 5-hydroxyindoleacetic acid was significantly lower in the AR and MX groups compared to non-PD controls; whereas, glycine was significantly higher in the AR group compared to the T, MX, and control groups. The results suggest that an operational approach can be utilized to differentiate between PD subtypes with distinct neurochemical profiles.

[1]  M. Scheinin.  Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity? , 1985, Medical biology.

[2]  J. Jankovic,et al.  Variable expression of Parkinson's disease , 1990, Neurology.

[3]  A. Lang,et al.  Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.

[4]  O. Ottersen,et al.  Terminals of subthalamonigral fibres are enriched with glutamate-like immunoreactivity: An electron microscopic, immunogold analysis in the cat , 1993, Journal of Chemical Neuroanatomy.

[5]  G. Stebbins,et al.  Factor structure of the unified Parkinson's disease rating scale: Motor examination section , 1998, Movement disorders : official journal of the Movement Disorder Society.

[6]  J. Nutt,et al.  Pharmacokinetics of levodopa. , 1984, Clinical neuropharmacology.

[7]  M. Merello,et al.  Depression in classic versus akinetic‐rigid Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[8]  A. Rajput,et al.  Prognostic significance of the onset mode in parkinsonism , 1993, Neurology.

[9]  G. Erba,et al.  The concentration of homovanillic and 5‐hydroxyindoleacetic acids in ventricular and lumbar CSF , 1972, Neurology.

[10]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[11]  J. Korf,et al.  Automated precolumn derivatization of amino acids, small peptides, brain amines and drugs with primary amino groups for reversed-phase high-performance liquid chromatography using naphthalenedialdehyde as the fluorogenic label. , 1990, Journal of chromatography.

[12]  D. McAdoo,et al.  Norepinephrine and serotonin release upon impact injury to rat spinal cord. , 1990, Journal of neurotrauma.

[13]  Wiklund Ra,et al.  First of two parts , 1997 .

[14]  L. Wolfson,et al.  Ventricular fluid homovanillic acid and 5‐hydroxyindoleacetic acid concentrations in patients with movement disorders , 1978, Neurology.

[15]  B. Roos,et al.  5-Hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid of patients with neurological diseases. , 1974, European neurology.

[16]  T. Kuwana,et al.  Determination of desmosine, isodesmosine, and other amino acids by liquid chromatography with electrochemical detection following precolumn derivatization with naphthalenedialdehyde/cyanide. , 1989, Analytical biochemistry.

[17]  A. H. Zwinderman,et al.  Rating impairment and disability in Parkinson's disease: Evaluation of the unified Parkinson's disease rating scale , 1994, Movement disorders : official journal of the Movement Disorder Society.

[18]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[19]  H. Mayberg,et al.  A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[20]  R. Marttila,et al.  DEMENTIA IN PARKINSON'S DISEASE , 1976, Acta neurologica Scandinavica.

[21]  P. Martínez-Martín,et al.  Unified Parkinson's disease rating scale characteristics and structure , 1994, Movement disorders : official journal of the Movement Disorder Society.

[22]  K. Y. Kim,et al.  Tremor at onset. Predictor of cognitive and motor outcome in Parkinson's disease? , 1991, Archives of neurology.

[23]  R. Marttila,et al.  Long-term responses of Parkinson's disease to levodopa therapy. , 1980, Journal of neural transmission. Supplementum.

[24]  K. Planansky.  Paralysis agitans: A clinical and genetic study , 1950 .

[25]  J. Brotchie,et al.  Chemical signalling in the globus pallidus in parkinsonism. , 1993, Progress in brain research.

[26]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[27]  J. Jankovic,et al.  The heterogeneity of Parkinson's disease , 1985, Neurology.

[28]  A. Barbeau,et al.  Le Journal Canadien Des Sciences Neurologiques New Data on the Genetics of Parkinson's Disease , 2022 .

[29]  K. Jellinger,et al.  The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease , 1991, Journal of neuropathology and experimental neurology.

[30]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[31]  J. Obeso,et al.  Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection , 1998, Annals of neurology.

[32]  T. Kuurne,et al.  Indole levels in human lumbar and ventricular cerebrospinal fluid and the effect of L‐tryptophan administration , 1985, Acta neurologica Scandinavica.

[33]  D. Brater,et al.  Goth's Medical Pharmacology , 1992 .

[34]  M. Kupersmith,et al.  Dementia in Parkinson disease , 1979, Annals of neurology.

[35]  P. Riederer,et al.  Distinction between benign and malignant type of parkinson's disease , 1979, Clinical Neurology and Neurosurgery.

[36]  M Richards,et al.  Interrater reliability of the unified Parkinson's disease rating scale motor examination , 1994, Movement disorders : official journal of the Movement Disorder Society.